Combining Cold Plasma and Acetyl Donor Molecules to Fight Diabetic Foot Ulcers and Airborne Viruses

AGA Nanotech is excited to announce a groundbreaking collaboration with the University of South Australia and Lancaster University to develop a novel solution to combat antimicrobial resistance (AMR) and diabetic foot ulcers. This joint research project has led to the discovery of a promising treatment that combines cold plasma gas with acetyl donor molecules, a proprietary technology owned by AGA Nanotech, to effectively kill resistant bacteria and viruses, including SARS-CoV-2, the virus responsible for COVID-19.

The collaboration is led by Dr. Endre Szili, a physicist at the University of South Australia, in partnership with Professor Rob Short from Lancaster University, AGA Nanotech, and the University of Bath. Their initial research focused on treating diabetic foot ulcers, which affect 15% of the world’s 415 million diabetics. The combination of cold plasma and acetyl donor molecules (TAED) has shown remarkable results in eradicating bacteria resistant to antibiotics. Quote: “By combining cold plasma with acetyl donor molecules to enhance its oxidation action, we found that the formulation completely killed bacteria found in chronic wounds,” said Dr. Szili, the lead researcher at UniSA. “We also tested its efficacy against the SARS-CoV-2 virus and found it achieved an 84% reduction in viral load, with potential for complete eradication.”

The acetyl donor molecule is a precursort technology, developed and patented by AGA Nanotech, that generates hydrogen peroxide and peracetic acid, which are powerful antimicrobial agents. This multi-action mechanism can disrupt biofilms when combined with cold plasma, the technology not only targets free-swimming bacteria but also effectively eradicates biofilms, a significant breakthrough in the treatment of chronic wounds.